WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

ratiopharm to become the hub for Teva's European growth strategy

Details
Financial
29 March 2010
Teva Pharmaceutical Industries Ltd.The ratiopharm Group gets a new owner. Subsequent to an extensive bidding process, the Israel-based company Teva Pharmaceutical Industries Ltd. is going to acquire the Ulm based company from Merckle Group's VEM asset management. The agreed enterprise value is € 3.625 billion.
Read more ...

Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results

Details
Financial
21 January 2009
Johnson & Johnson has announced sales for the year 2008 of $63.7 billion, an increase of 4.3% over 2007. Operational growth was 1.9% with currency contributing 2.4%. Domestic sales decreased 0.4%, while international sales increased 9.7%, reflecting operational growth of 4.6% and a positive currency impact of 5.1%. Worldwide sales in the fourth quarter of 2008 were $15.2 billion, a decrease of 4.9% as compared to the fourth quarter of 2007.
Read more ...

Johnson & Johnson Announces Definitive Agreement to Acquire Omrix

Details
Financial
25 November 2008
Johnson & Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, have announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer.
Read more ...

Alpharma Responds To Unsolicited Proposal By King Pharmaceuticals, Inc.

Details
Financial
25 August 2008
Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, confirmed that it received an unsolicited, non-binding proposal from King Pharmaceuticals, Inc. (NYSE: KG) to acquire all of the outstanding shares of Alpharma for $33.00 per share in cash. Alpharma said that proposal was identical in all material respects to two prior proposals made privately by King to the company.
Read more ...

King Proposes Acquisition of Alpharma for $33 Per Share in Cash

Details
Financial
24 August 2008
King Pharmaceuticals, Inc. (NYSE: KG) announced that it has submitted to the Board of Directors of Alpharma Inc. (NYSE: ALO) a proposal to acquire all of the outstanding shares of common stock of Alpharma for $33.00 per share in cash. The proposal is not conditioned on financing.
Read more ...

Teva Reports Second Quarter 2008 Results - Record Quarterly Sales of $2,823 Million

Details
Financial
13 August 2008
Teva Pharmaceutical Industries Ltd.Net sales for the second quarter of 2008 increased 18 percent to $2,823 million, compared to $2,386 million in the second quarter of 2007. Net income for the second quarter of 2008 totaled $539 million, compared to $515 million for the same period of 2007 (up 5 percent), while diluted earnings per share increased to $0.65 from $0.63 (up 3 percent).
Read more ...

Grindeks profit reaches 5 million lats in the first half of 2008

Details
Financial
10 August 2008
JSC GrindeksThe financial statements of the JSC Grindeks for the first half of the year 2008, submitted to Riga Stock Exchange, certify that the Group of Grindeks has operated successfully during the first six months of this year. The net profit during the reporting period is 5 million lats, which is by 43% more than in the first half of 2007.
Read more ...

More Pharma News ...

  1. PLIVA Announces H1 2008 Results
  2. The Medicines Company Reports First Quarter 2008 Financial Results
  3. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
  4. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline
  5. The Medicines Company Reports Full Year and Fourth Quarter 2007 Financial Results
  6. Teva to acquire CoGenesys with a purchase price of $400 million cash
  7. Merz Group experiences successful 2006/07 financial year
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
  • A new technology offers treatment for HIV infection through a single injection

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Financial
  4. Teva Reports Second Quarter 2008 Results - Record Quarterly Sales of $2,823 Million

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.